Summarized by Masters of Longevity from PR Newswire.
The global Phase 2 trial enrolled about 324 GA patients to test xelafaslatide.

Key Takeaways
- GALAXY enrolled about 324 patients across three regions.
- Xelafaslatide is given by intravitreal injection at varied schedules.
- Topline 48-week efficacy data are expected in Q4 2027.



